Recent study looking at enzalutamide as a second line therapy for those mCRPC progressing on abiraterone. Based on info below, I am curious as to how Zenith arrived at their standard of care and target lines on slide 14 of their Bio-Europe presentation showing progression free survival. Has Zenith really shown yet that the combo exceeds expectations of enzalutamide alone?

"Results: A total of 215 pts were enrolled; 214 were treated with ENZA (median age, 73 years). The analysis was performed on data up to 48 weeks after the last pt started ENZA treatment. Median duration of prior Abi therapy was 54 weeks. The median duration of ENZA treatment was 5.7 months: 12 months in PSA responders and 4.6 months in non-PSA responders."

Efficacy and safety of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (Abi): A multicenter, single-arm, open-label study.

Second-Line Enzalutamide May Benefit Some mCRPC Patients

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe